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ABSTRACT
Aims/Introduction: The efﬁcacy, dose–response relationship and safety of ginsam, a vinegar extract from Panax ginseng,w e r e
evaluated in an 8-week, double-blind, randomized, placebo-controlled study in drug-naı ¨ve patients with type 2 diabetes.
Materials and Methods: A total of 72 diabetic patients were randomized to receive 1500, 2000 or 3000 mg of ginsam, or placebo
daily for 8 weeks (n =1 8i ne a c hg r o u p ) .T h ep r i m a r ye n d - p o i n tw a st h ec h a n g e sf r o mt h eb a s e l i n eH b A 1c level. The secondary
end-points were the changes of fasting and postprandial 2-h glucose concentration, and the proportion of patients achieving a
reduction in HbA1c >0.5%.
Results: In the intention-to-treat analysis, ginsam treatment reduced HbA1c level signiﬁcantly: )0.56 ± 0.25% in the 1500 mg group,
)0.31 ± 0.12% in the 2000 mg group, and )0.29 ± 0.11% in the 3000 mg group (all P < 0.05), with a signiﬁcant difference between
the 1500 mg ginsam and the placebo group ()0.02 ± 0.12%, P = 0.021). The changes in fasting glucose concentration followed
the same pattern: )21.40, )14.27 and )6.76 mg/dL for 1500, 2000, and 3000 mg, respectively, vs )2.25 mg/dL for the placebo.
T h ep e r c e n t a g eo fp a t i e n t sw h o s eH b A 1c level decreased by >0.5% differed signiﬁcantly between the placebo group (11.1%) and
the 1500 mg (27.8%) and 2000 mg (27.8%) groups. No severe adverse events were observed in any group.
Conclusions: An 8-week treatment with ginsam, a vinegar extract from P. ginseng, moderately improved HbA1c level and
was well tolerated in type 2 diabetic patients with inadequate glycemic control. This trial was registered with ClinicalTrial.Gov
(no. NCT01008163). (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00185.x, 2012)
KEY WORDS: Ginsam, Oral antidiabetic therapy, Panax ginseng
INTRODUCTION
Ginseng is one of the most popular oriental herbal medicines.
Ginseng was originally referred to as the root of Panax ginseng
CA Mey. In traditional oriental medicine, ginseng is considered
an adaptogen, aphrodisiac and nourishing stimulant, and has
been used historically in the treatment of various aging-associ-
ated diseases
1,2.
The various pharmacological properties of ginseng have been
documented
3–5. Several studies showed that ginseng had anti-
diabetic effects
6,7. In addition, the berry and leaf of ginseng have
been reported to lower blood glucose concentration and body-
weight in models of diabetes and obesity
8,9.M o s ts t u d i e su s e
simple extracts from the roots, leaves or berries of ginseng,
which contain various concentrations of saponins and non-
saponins. Ginsenosides, which belong to the saponin family, are
the major active compounds of ginseng, and more than 30
ginsenosides have been isolated from ginseng
10. Among these
ginsenoside components, Rg3 is thought to be one of the most
active components in terms of its pharmacological effects of
ginseng on glucose and lipid levels, as well as obesity
11–13.A
substantial effort has been focused on improving the pharmaco-
logical properties of ginseng by extracting the most biologically
active components.
Ginsam is a vinegar extraction from P. ginseng that is
enriched with ginsenoside Rg3
14. A study comparing the effects
of ginsam and unprocessed ginseng extracts in an animal model
of metabolic syndrome found that ginsam decreased insulin
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unprocessed ginseng extracts
14. In our previous study, ginsam
had distinct beneﬁcial effects on glucose metabolism and body-
weight control in an obese animal model of insulin resistance by
changing the expression of genes involved in glucose and fatty
acid metabolism
15. Our group has also reported that Rg3
improves insulin signaling and glucose uptake primarily by
stimulating the expression of insulin receptor substrate-1 and
GLUT4
12. However, no study has investigated the glucose-
lowering effect of ginsam in humans. Identifying the proper
dosage of extracts from ginseng associated with antihyperglyce-
mic activity might help develop a new class of antidiabetic agent.
We evaluated the efﬁcacy, dose–response relationship and safety
of ginsam, a vinegar extract from P. ginseng. We measured the
concentrations of biomarkers, such as high-sensitivity C-reactive
protein (hsCRP), tumor necrosis factor-a (TNF-a), interleukin-6
(IL-6), adiponectin and leptin, to identify any links between
the glucose-lowering effect of ginsam and changes in these
biomarkers.
MATERIALS AND METHODS
Patients
The inclusion criteria included patients older than 18 years and
who had type 2 diabetes without any antidiabetic medication for
more than 3 months, fasting plasma glucose (FPG) concentra-
tion in the range 7.0–15.0 mmol/L and HbA1c level of
7.0–12.0% (53–108 mmol/mol). The exclusion criteria included
subjects who had type 1 diabetes or secondary diabetes; had
chronic hepatitis (except healthy hepatitis B virus carriers) or
active liver diseases (aspartate aminotransferase [AST] or alanine
aminotransferase [ALT] greater than twice the upper normal
value), serum creatinine concentration >1.5 mg/dL or a history
of malignant neoplasm in the previous 5 years; or were taking
medication that can affect glycemic control, such as systemic
glucocorticoids; or women who were pregnant or lactating, and
women of childbearing potential who intended to become preg-
nant or who did not agree to use adequate contraceptive meth-
ods during the study. Patients taking any other active
ingredients, plant extracts or other complementary therapies
contributing to blood glucose lowering potentials were excluded.
A total of 96 patients were screened, and 24 patients were
excluded. Of those excluded, 11 had HbA1c levels >12%
(108 mmol/mol), seven had active liver diseases and four took
medications that could affect the study results. Another two
patients withdrew their consent without giving a reason. Finally,
72 patients (44 men and 28 women) with inadequate glycemic
control (7.0–9.0% [53–75 mmol/mol] of HbA1c), despite medi-
cal nutritional therapy and exercise, were selected. A total of 11
patients (15.3%) dropped out during the study period: three in
the control group, three in the 1500 mg ginsam group, four in
the 2000 mg ginsam group and one in the 3000 mg ginsam
group (Figure 1).
Each patient’s medical history, including use of medication
and lifestyle details, such as alcohol intake, smoking status and
exercise habits, were recorded by trained nurses. All assessments
were carried out at Seoul National University Bundang Hospital
in Seongnam, Korea, from January 2008 through to June 2009.
The study was approved by the institutional review board of
Seoul National University Bundang Hospital (IRB No. B-0708/
048-002), and all patients gave written, informed consent.
The present study was carried out after registration at
ClinicalTrials.gov (NCT 01008163).
Study Design
This was a double-blind, placebo-controlled, randomized study.
Patients were randomized into one of four groups: 1500 mg
(500 mg t.i.d.), 2000 mg (1000 mg b.i.d. + placebo before lunch)
or 3000 mg (1000 mg t.i.d.) of ginsam (YuYu Pharmaceutical,
Seoul, Korea), or a matching placebo (t.i.d.). The dosage of gin-
sam in the present study was determined on the basis of previ-
ous clinical studies
16,17. Ginsam or placebo was taken three
times daily before meals during the 8-week study. The taste and
smell of the placebo was the same as the active agent. The study
was double-blind, and a permuted block-randomization method
was used. We provided pertinent diabetes education, including
a therapeutic lifestyle change program, to standardize every
patient’s education level. The study participants were scheduled
to visit the research laboratory at baseline and after 4 and
8 weeks of treatment, and were monitored, as a withdrawal cri-
terion was a FPG concentration of ‡15.0 mmol/L. Compliance
with medication was assessed by pill count at every visit.
Study End-points
The primary end-points were to investigate the efﬁcacy of gin-
sam treatment by comparing the changes from baseline in
HbA1c levels after 8-week treatment between the ginsam groups
and placebo group. The secondary efﬁcacy end-points were:
(i) FPG concentration and 2-h postload glucose (2-h PG) con-
centration after a 75-g oral glucose tolerance test (OGTT) at
8 weeks; (ii) the proportion of patients achieving a glycemic
response, which was deﬁned as a reduction in HbA1c level of
>0.5%; (iii) changes from baseline in the homeostasis model
assessment of insulin resistance (HOMA-IR) and b-cell function
(HOMA-B), and quantitative insulin sensitivity check index
(QUICKI); and (iv) changes from baseline in biomarker levels
(hsCRP, TNF-a,I L - 6 ,a d i p o n e c t i na n dl e p t i n ) .
The safety end-points included adverse events (AE), serious
adverse events (SAE), hypoglycemia, and changes in blood
pressure, liver and renal functions. The relationships between
AE and treatment were classiﬁed as certain, probable, possible,
unlikely, not related or not assessable. A SAE was deﬁned as an
AE that resulted in death, threat to life, admission to hospital
or the prolongation of in-patient treatment, de novo cancer, or
any other important medical events in the opinion of the inves-
tigators. Patients were educated to measure their blood glucose
concentration whenever they experienced a hypoglycemic
symptom and to record the blood glucose value in a diary. This
entry was transcribed in the AE form by study nurses.
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To evaluate the effects of ginsam on glucose metabolism, plasma
glucose and insulin concentrations were measured after a 12-h
fast, and all patients completed a 75-g OGTT. Plasma glucose
concentration was measured using the glucose oxidase method.
Plasma insulin concentration was measured by radioimmuno-
assay (Linco Research, St Charles, MO, USA). Plasma glucose
concentration was also measured at 2 h after the 75-g OGTT.
HbA1c level was measured by ion-exchange high-performance
liquid chromatography. The HOMA-IR, HOMA-B and
QUICKI were calculated as described previously
18,19.
Measurement of Other Biomarkers Related to Glucose
Metabolism: hsCRP, Adiponectin, TNF-a,I L - 6a n dL e p t i n
Concentrations
High sensitivity CRP concentration was measured by immuno-
nephelometry. Circulating adiponectin concentration was mea-
sured using an enzyme-linked immunosorbent assay kit
(AdipoGen, Seoul, Korea). The intra- and interassay coefﬁcient
of variation was 3.3 and 7.4% in adiponectin. Plasma TNF-a,
IL-6 and leptin concentrations were measured using multiplex
kits (Linco Research).
Statistical Analyses
The present phase II study aimed to investigate the level of
glucose lowering effects of ginsam without superiority or non-
inferiority hypothesis testing for treatment differences among
groups. A 95% conﬁdence interval for the difference in HbA1c
levels after 8-week treatment with a total width of 0.8% of
HbA1c (absolute) based on previous studies
10,15,20 was regarded
as sufﬁcient for this exploratory trial and would be obtained
with 72 completed participants in the placebo and ginsam
g r o u p s .W ea l l o c a t e d1 8p a t i e n t st ot h ep l a c e b og r o u pa n d5 4
patients to the three ginsam groups (n = 18 each) without pre-
speciﬁed conﬁrmatory hypotheses. A withdrawal rate was
assumed to be 15%. Both intention-to-treat and per protocol
analyses were carried out for the efﬁcacy analysis and safety
proﬁle.
Data are expressed as mean ± SD and were analyzed using
SPSS W i n d o w sv e r s i o n1 4 . 0( S P S S ,C h i c a g o ,I L ,U S A ) .C h a n g e s
Enrolment
Assessed for eligibility (n = 96)
Excluded (n = 24)
• Not meeting inclusion criteria (n = 18)
• Declined to participate (n = 2)
• Other reasons (n = 4)
Randomized (n = 72)
Allocation
Follow-up
Analysis
Allocated to placebo treatment (n = 18) Allocated to Ginsam treatment
• G2000 (n = 18)
• G3000 (n = 18)
Discontinued intervention
Intention-to-treat analysis (n = 54) Intention-to-treat analysis (n = 18)
Per protocol analysis (n = 46) Per protocol analysis (n = 15)
• Excluded from analysis (n = 3)
Discontinued intervention
• G1500 (n = 18)
• G2000 (n = 14)
• G3000 (n = 17)
• G1500 (n = 15)
• G1500 (n = 3) • Placebo (n = 3)
• G2000 (n = 4)
• G3000 (n = 1)
– High fasting glucose (n = 1)
– High glucose (n = 2)
– Drug adverse eﬀects (n = 2)
– Drug adverse eﬀects (n = 2)
– High fasting glucose (n = 1)
– Drug adverse eﬀects (n = 2)
– Drug adverse eﬀects (n = 1)
Figure 1 | Flow chart of enrolment of the study subjects.
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Antidiabetic effect and safety of ginsamin parameters from the baseline values were evaluated using
paired t-tests. The signiﬁcance of differences in the changes in
parameters between groups was evaluated using ANOVA and
post-hoc testing. The percentages of patients achieving a reduc-
tion in the HbA1c level of >0.5% and the frequency of AE were
compared using the v
2 test. P-values <0.05 were considered to
be statistically signiﬁcant.
RESULTS
A total of 72 patients with type 2 diabetes were randomly
divided into four groups (ginsam 1500, 2000 and 3000 mg, and
placebo, n = 18 each). Figure 1 shows the ﬂow of enrolment
and end-points of the study subjects. The baseline demographics
and disease characteristics were not signiﬁcantly different
between groups (Table 1). Medical history, use of other medica-
tions and lifestyles, such as smoking status, alcohol consumption
and diet habit, were not different between the groups (data not
shown). On average, patients in each group were moderately
hyperglycemic (mean HbA1c 7.6–7.8% [60–62 mmol/mol] for
each group) at baseline.
The between-treatment difference in drug compliance was
assessed for the ginsam and placebo groups. The percentage of
pills consumed during the 8 weeks did not differ between
groups: 96.4% in the ginsam group and 92.6% in the placebo
group. The proportion of pills consumed also did not differ
signiﬁcantly among the three ginsam groups.
Table 1 | Baseline characteristics according to treatment group
Placebo Ginsam 1500 mg Ginsam 2000 mg Ginsam 3000 mg P*
Mean SD Mean SD Mean SD Mean SD
Age (years) 54.8 10.0 52.7 11.0 52.7 10.0 51.1 8.6 NS
Male n (%)
† 11 61.1 9 50 11 61.1 13 72.2 NS
Duration of diabetes 2.4 2.7 2.7 2.9 3.7 3.7 2.7 2.9 NS
Height (cm) 163.7 8.3 163.0 7.5 165.4 6.5 166.2 6.8 NS
Weight (kg) 67.9 8.6 70.2 15.2 65.9 9.3 70.2 7.8 NS
SBP (mmHg) 125.9 16.0 125.2 9.8 126.2 12.3 122.9 13.0 NS
DBP (mmHg) 76.3 10.1 75.6 8.2 78.2 8.6 79.2 11.3 NS
BMI (kg/m
2) 25.3 1.9 26.3 4.8 24.0 2.6 25.4 2.7 NS
Waist circumference (cm) 89.9 6.7 91.6 9.8 86.3 8.8 88.8 7.0 NS
Fasting glucose (mmol/L) 8.25 1.80 9.15 2.24 9.54 1.96 8.95 1.49 NS
Postload 2-h glucose (mmol/l) 15.51 2.84 17.52 4.83 16.57 4.84 16.82 4.12 NS
Fasting insulin (pmol/L) 68.76 29.17 80.56 39.59 65.98 30.56 84.03 45.84 NS
HbA1c (%) 7.6 0.4 7.8 1.3 7.8 1.2 7.7 0.8 NS
HbA1c (mmol/mol) 60 7 62 12 62 13 61 9 NS
Total cholesterol (mmol/L) 5.04 0.80 5.68 1.06 5.31 1.07 5.23 0.78 NS
Triglyceride (mmol/L) 1.67 0.53 2.00 1.03 1.67 0.73 2.05 1.63 NS
HDL-cholesterol (mmol/L) 1.45 0.28 1.35 0.36 1.32 0.47 1.21 0.28 NS
LDL-cholesterol (mmol/L) 2.62 0.61 3.03 0.74 2.92 0.80 2.82 0.59 NS
AST (IU/L) 24.1 7.7 26.3 7.3 24.3 6.8 23.4 8.9 NS
ALT (IU/L) 26.4 12.5 33.2 11.8 27.2 10.2 27.0 13.7 NS
cGT (IU/L) 44.1 35.9 55.5 38.5 43.2 36.5 37.9 17.0 NS
Creatinine (mg/dL) 1.02 0.19 0.98 0.21 0.92 0.17 0.96 0.08 NS
HOMA-IR 3.8 2.1 4.7 2.5 4.1 2.0 4.9 2.9 NS
HOMA-B 43.5 14.3 47.8 29.7 34.1 17.9 46.4 26.7 NS
QUICKI 0.54 0.07 0.51 0.05 0.53 0.06 0.51 0.07 NS
hsCRP (mg/L) 0.14 0.29 0.23 0.24 0.13 0.16 0.16 0.13 NS
TNF-a (pg/mL) 7.9 3.5 8.9 5.8 7.3 5.7 8.5 8.1 NS
IL-6 (pg/mL) 24.2 29.3 25.5 30.6 31.5 43.7 24.0 22.4 NS
Adiponectin (lg/mL) 8.6 4.4 9.4 6.4 9.4 4.1 9.1 5.0 NS
Leptin (pg/mL) 9.2 11.8 9.5 9.3 7.7 5.1 8.7 11.0 NS
Antihypertensive med.† 3 16.7% 2 11.1% 3 16.7% 2 11.1% NS
L i p i dl o w e r i n gm e d . † 2 11.1% 1 5.6% 2 11.1% 3 16.7% NS
*Signiﬁcant difference between groups by one-way ANOVA. †Data are n and %. ALT, alanine aminotransferase; AST, aspartate aminotransferase;
BMI, body mass index; CRP, c-reactive protein; DBP, diastolic blood pressure; cGT, c-glutamyl transferase; HOMA-B, homeostasis model assessment for
b-cell function; HOMA-IR, homeostasis model assessment for insulin resistance; IL-6, interleukin-6; med., medication; NS, not signiﬁcant; QUICKI,
quantitative insulin sensitivity check index; SBP, systolic blood pressure; TNF-a, tumor necrosis factor-a.
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Yoon et al.Primary End-point
HbA1c Level
For the primary end-point of the present study, the change in
HbA1c level signiﬁcantly differed between the placebo and
1500 mg ginsam groups (P = 0.021 in the intention-to-treat
analysis and P = 0.014 in the per protocol analysis), but not
between the placebo and other ginsam groups (Figure 2).
Within individual groups, treatment with ginsam for 8 weeks
reduced the HbA1c level signiﬁcantly relative to the baseline val-
ues: in the intention-to-treat analysis, )0.56 ± 0.25% in the
1500 mg group (P = 0.034), )0.31 ± 0.12% in the 2000 mg
group (P = 0.042) and )0.29 ± 0.11% in the 3000 mg ginsam
group (P = 0.025) compared with the placebo group
()0.02 ± 0.12%, P = 0.267). In the per protocol analysis, a simi-
lar trend was found with greater glucose lowering efﬁcacy in the
ginsam group: )0.59 ± 0.25, )0.34 ± 0.12 and )0.33 ± 0.11%
in the 1500, 2000 and 3000 mg groups, respectively, and
)0.01 ± 0.12% in the placebo group. When one outlier who
showed DHbA1c > 1.5% in the ginsam 1500 mg arm was
excluded, DHbA1c (%) decreased from 0.56 ± 0.25 to
0.45 ± 0.23 in this arm with borderline signiﬁcance (P = 0.087).
As a secondary analysis, when DHbA1c was compared between
placebo and combined ginsam groups, there was signiﬁcant dif-
ference in DHbA1c between the two arms irrespective of includ-
ing the outlier: placebo vs combined ginsam groups with outlier,
)0.02 ± 0.12% vs 0.38 ± 0.09% and placebo vs combined
ginsam group without outlier, )0.02 ± 0.12% vs 0.36 ± 0.07%,
both P < 0.01).
Secondary End-Points
FPG and 2-h PG Concentrations
FPG concentration tended to decrease after ginsam treatment.
The mean changes in FPG concentration from baseline to
8 weeks were )0.12 ± 1.62 mmol/L (P = 0.719) in the placebo
group and )1.19 ± 0.85 mmol/L (P = 0.021), )0.79 ± 1.28
mmol/L (P = 0.094), and )0.38 ± 0.91 mmol/L (P = 0.119) in
the 1500, 2000 and 3000 mg ginsam groups, respectively. There
was a statistical signiﬁcance between the change in the placebo
and 1500 mg ginsam groups (P = 0.043; Figure 2).
The mean changes in 2-h PG concentration from baseline to
8 weeks were )1.18 ± 1.62 mmol/L (P = 0.262) in the placebo
group, and )2.32 ± 3.01 mmol/L (P = 0.047), )1.03 ± 2.36
mmol/L (P = 0.179) and )1.73 ± 2.79 mmol/L (P = 0.054) in
the 1500, 2000 and 3000 mg ginsam groups, respectively. The
changes in 2-h PG concentration did not differ signiﬁcantly
between the placebo and ginsam-treated groups.
Potency of the Glucose-lowering Effect (HbA1c Level By >0.5%)
and Changes in the Index of Insulin Resistance and b-Cell
Function
The percentage of patients whose HbA1c decreased by >0.5%
differed signiﬁcantly between the placebo group (11.1%) and the
1500 mg ginsam (27.8%) and 2000 mg ginsam (27.8%) groups,
but not between the placebo and 3000 mg ginsam (16.7%)
groups (Figure 2). However, the percentage of patients achieving
a glycemic response, deﬁned as a HbA1c level of £7.0%
(53 mmol/mol) at 8 weeks, did not differ between groups. This
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Figure 2 | Changes of HbA1c level, and fasting and postload glucose concentration and percentage of patients whose HbA1c decreased by >0.5%
during 8 weeks of treatment with ginsam.
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Antidiabetic effect and safety of ginsamresult might be attributed to the differences in the baseline
HbA1c levels, albeit statistically non-signiﬁcant. The changes in
HOMA-B, HOMA-IR and QUICKI, which are indicators of
insulin secretory function and insulin resistance, did not differ
signiﬁcantly between groups (Table 2).
Changes in Biomarkers (Concentrations of Adiponectin, hsCRP,
TNF-a, IL-6 and Leptin) From Baseline
Adiponectin concentration did not change signiﬁcantly during
the 8 weeks in the placebo or ginsam groups. TNF-a concentra-
tion in all ginsam groups and IL-6 concentration in the
1500 mg ginsam group decreased signiﬁcantly after 8 weeks
(P < 0.05). TNF-a concentration after the 8-week treatment was
signiﬁcantly lower in the 1500 and 3000 mg ginsam groups than
in the placebo group. The plasma concentrations of hsCRP and
leptin did not change signiﬁcantly after 8 weeks of treatment in
any group (Table 2).
Other Parameters
Bodyweight, body mass index and waist circumference did not
differ between groups, and did not change during the 8 weeks.
Low-density lipoprotein cholesterol concentration decreased
slightly, by 0.24 ± 0.37 mmol/L in the 1500 mg ginsam group
(P = 0.089). Other lipid concentrations did not change signiﬁ-
cantly after the 8 weeks in any group (Table 2).
Correlations Between Changes in HbA1c Level and Biomarkers
Because TNF-a and IL-6 concentrations were decreased after
ginsam treatment, correlation analysis was carried out to investi-
gate the relationships between the changes in HbA1c level and
t h e s em a r k e r s .T h ec h a n g ei nH b A 1c level of ginsam treatment
correlated positively and signiﬁcantly with the changes in TNF-a
and IL-6 concentrations (Figure 3).
Tolerability and Safety
Overview of AE
AE were reported by 11 (61.1%) patients treated with the pla-
cebo and by 36 (63.0%) patients treated with ginsam: 14 in the
1500 mg, 11 in the 2000 mg and 11 in the 3000 mg ginsam
group. The most commonly reported AE were general weakness
(16.7%) and gastrointestinal disturbance (11.1%) in the pla-
cebo group, and general weakness (16.7%), gastrointestinal
Table 2 | Changes of anthropometric and biochemical parameters after 8 weeks of Ginsam treatment
P l a c e b o G i n s a m1 5 0 0m g G i n s a m2 0 0 0m g G i n s a m3 0 0 0m g P*
Mean SD Mean SD Mean SD Mean SD
DSBP (mmHg) )0.55 12.33 1.22 10.91 1.55 14.18 )1.75 10.51 NS
DDBP (mmHg) )1.45 6.74 1.56 7.04 3.27 5.62 )2.83 9.90 NS
DBMI (kg/m
2) 0.06 0.94 0.29 0.30 0.06 0.45 0.23 0.42 NS
DWaist circumference (cm) 0.50 2.12 0.79 1.20 0.89 3.12 )0.33 3.99 NS
DFasting glucose (mmol/L) 0.12 1.62 1.19 0.85 0.79 1.28 0.38 0.91 A
D2-h PG (mmol/L) 1.18 1.62 2.32 3.01 1.03 2.36 1.73 2.79 NS
DHbA1c (%) 0.02 0.43 0.56 0.62 0.31 0.32 0.29 0.34 A
DInsulin (pmol/L) )0.35 33.06 5.07 30.14 )5.49 22.71 )4.10 16.74 NS
DTotal cholesterol (mmol/L) )0.05 0.88 0.37 0.72 0.18 0.74 0.24 0.69 NS
DTriglycerides (mmol/L) )0.05 0.40 0.15 1.02 0.11 0.53 0.18 1.03 NS
DHDL-cholesterol (mmol/l) 0.04 0.19 0.01 0.18 0.01 0.12 0.04 0.12 NS
DLDL-cholesterol (mmol/L) )0.06 0.61 0.24 0.37 0.17 0.42 0.25 0.67 NS
DAST (IU/L) 2.36 4.50 5.11 4.34 1.00 4.36 4.92 5.14 NS
DALT (IU/L) 3.91 6.12 8.89 10.24 2.09 6.80 7.38 11.67 NS
DcGT (IU/L) 2.27 14.04 15.33 30.98 5.00 11.09 )3.15 18.15 NS
DCreatinine (mg/dL) 0.08 0.02 0.12 0.09 )0.16 0.12 0.14 0.12 NS
DHOMA-IR 0.25 1.89 0.66 1.32 )0.24 2.20 )0.06 1.19 NS
DHOMA-B )5.25 27.87 )2.87 26.14 )6.29 9.62 )4.84 10.24 NS
DQUICKI 0.01 0.07 )0.02 0.06 )0.01 0.04 0.01 0.03 NS
DhsCRP (mg/L) )0.01 0.06 0.05 0.28 0.06 0.17 )0.01 0.09 NS
DTNF-a (pg/mL) )0.09 3.21 2.48 2.32 1.73 1.80 2.20 3.42 A,C
DIL-6 (pg/mL) 1.72 10.41 10.11 12.83 8.44 19.19 7.06 14.91 NS
DAdiponectin (lg/mL) )0.47 2.05 )0.50 2.27 )0.70 1.34 )1.19 3.74 NS
DLeptin (pg/mL) 0.67 2.54 0.18 2.38 0.38 2.76 )0.53 2.08 NS
*Statistical signiﬁcance by ANOVA between groups. Post-hoc analysis by least-signiﬁcant difference (mean difference between groups, P <0 . 0 5i na l l
cases). A, placebo vs 1500 mg; ALT, alanine aminotransferase; AST aspartate aminotransferase; B, placebo vs 2000 mg; C, placebo vs 3000 mg; cGT,
c-glutamyl transferase; HOMA-B, homeostasis model assessment for b-cell function; HOMA-IR, homeostasis model assessment for insulin resistance;
IL-6, interleukin-6; PG, postload glucose; QUICKI, quantitative insulin sensitivity check index; TNF-a, tumor necrosis factor-a.
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Yoon et al.disturbance (9.3%), upper respiratory infection (9.3%), musculo-
skeletal pain (7.4%) and pruritus (3.7%) in the ginsam-treated
groups (Table S1). The double-blind therapy was discontinued
as a result of all-cause AE in ﬁve (9.3%) ginsam-treated patients
and in two (11.1%) placebo-treated patients; the difference was
not signiﬁcant. No SAE were reported in any group, and no
patient reported hypoglycemic symptoms during the study.
B l o o dP r e s s u r ea n dB i o c h e m i c a lP a r a m e t e r s
The changes in systolic and diastolic blood pressure did not dif-
fer signiﬁcantly between groups. Within- and between-treatment
differences in liver function, as assessed by AST, ALT and
c-glutamyl transferases levels, and in renal function, as assessed
by serum creatinine concentration, were not signiﬁcant.
DISCUSSION
In the present study, ginsam, which was produced by vinegar
extraction from P. ginseng to yield high concentrations of ginse-
noside Rg3, showed possible glucose-lowering effects in drug-
naı ¨ve patients with type 2 diabetes. The percentage of patients
achieving >0.5% HbA1c reduction was greater in the ginsam-
treated group than in the placebo group. This glucose-lowering
effect was possibly attributable to the inﬂammatory process
where TNF-a and IL-6 concentrations were decreased after
ginsam treatment, and their changes were correlated with the
changes in HbA1c level.
Various standardized formulas of ginseng products have been
introduced
4. Different preparation methods for processing
ginseng products, and variable ages and species of ginseng contrib-
ute to the variability in the ginsenoside composition and the anti-
hyperglycemic efﬁcacy of individual ginseng products
6,9,14,20–22.
Among the many bioactive compounds contained in ginseng,
the most representative active compounds are ginseng-speciﬁc
saponins (ginsenosides)
8. Ginsenosides are comprised of a
steroid skeleton and sugar moieties, and the type, number and
position of the sugars determine its structure and function.
Among the known species of ginsenosides, ginsenosides Rg1,
Rh2, Rb1, Re and Rg3 have been reported to have glucose-
lowering effects in animal studies
10,13,23,24. Recently, Reeds
et al.
25 reported that ginsenoside Re therapy does not improve
b-cell function or insulin sensitivity in overweight/obese subjects
with impaired glucose tolerance or newly diagnosed diabetes. In
the current study, we used ginsam, which was enriched with
Rg3 and the main component of steam-treated ginseng (red
ginseng) or acid-treated ginseng
26. In an animal study, treatment
of ginsam improved the metabolic proﬁle in high-fat fed ICR
mice
14. We reported recently that ginsam treatment decreased
glucose excursion during the intraperitoneal glucose tolerance
test by 21.5% in an obese insulin-resistant rat model
15.T h e s e
beneﬁcial effects of ginsam were related to an increased GLUT4
protein level in skeletal muscle, and increased peroxisome prolif-
erator-activated receptor-c protein level and AMP-activated pro-
tein kinase phosphorylation in liver and skeletal muscle. Rg3
enhanced both basal and insulin-induced glucose uptake in a
dose-dependent manner and increased the levels of phosphory-
lated IRS-1/Akt and GLUT4 mRNA
12.
Furthermore, there have been several studies documenting the
role of Rg3 in improving pancreatic b-cell function. A group
reported that Rg3 increased glucose-stimulated insulin secre-
tion
13, and another group showed that Rg3 suppressed palmi-
tate-induced apoptosis of pancreatic b-cell lines
27.
Interestingly, the ginsam-induced improved glucose homeo-
stasis was associated with decreased concentrations of pro-
inﬂammatory cytokines, TNF-a and IL-6, in the current study.
Many studies have provided evidence of a critical role of TNF-a
and IL-6 in the pathogenesis of diabetes and its complications
through impairment of insulin signaling
28–30, leading to a surge
of interest in ﬁnding new antidiabetic agents that suppress the
inﬂammatory pathway
31. A recent study reported that a fer-
mented form of P. ginseng protected against pancreatic b-cell
damage by downregulating induc i b l en i t r i co x i d es y n t h a s ea n d
TNF-a gene expression by blocking nuclear factor kappa B
activities
22. These data, along with the current study results, pro-
vide evidence for the anti-inﬂammatory and anti-oxidative
effects of ginsam that contributed to improvement of glucose
metabolism.
In the present study, treatment with ginsam for 8 weeks sig-
niﬁcantly reduced HbA1c level by 0.29–0.56%, which was lower
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Figure 3 | Correlations between the changes of HbA1c and the
changes of tumor necrosis factor-a (TNF-a) or interleukin-6 (IL-6) levels.
The changes of HbA1c were positively and signiﬁcantly correlated with
changes of TNF-a and IL-6.
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Antidiabetic effect and safety of ginsamthan the potency of other oral antidiabetic agents proved in
Korean drug-naı ¨ve type 2 diabetic patients
32.F u r t h e r m o r e ,a
dose–response relationship was not found. The reason for the
lack of a linear relationship is not entirely clear. Drug compli-
ance did not differ signiﬁcantly between groups. It is possible
that the dose range studied was too high, as was the case in a
previous study
16 and that a threshold of around 1500 mg of
ginsam might be the most effective in improving glucose
homeostasis. Also, the 8-week treatment period might not have
been long enough to assess the full effect of ginsam on glucose
control.
Currently available oral antidiabetic drugs have a number of
adverse effects, such as hypoglycemia, lactic acidosis and weight
gain
33. In the present study, ginsam was well tolerated, as there
were no treatment-related SAE and the frequency of side-effects
did not differ signiﬁcantly between the ginsam and placebo
groups. The number of patients who stopped the study medica-
tion for any reason did not differ between the ginsam and
placebo groups (9.3% vs 11.1%). In addition, treatment with gin-
sam was at least weight neutral and did not cause hypoglycemia.
Furthermore, ginsam did not alter hepatic or renal functions
and did not modify cardiovascular risk factors, such as blood
pressure or lipid proﬁle.
T h e r ew e r es o m el i m i t a t i o n si nt h ep r e s e n ts t u d y .F i r s t ,t h e
gold standard technique for evaluating pancreas b-cell function
and insulin resistance, such as clamp study, were not used. Sec-
ond, the study duration of 8 weeks did not allow assessment of
long-term results. Given the positive impact of low dose ginsam,
it is conceivable that longer-term ginsam use would result in a
more durable glucose lowering effect. Third, just 18 patients
were assigned to four respective arms, although 72 patients were
enrolled as a whole. The relatively small number in each arm
might be associated with weak signiﬁcance. Finally, the baseline
characteristics among the study groups were not strictly
comparable, even though the differences were not statistically
signiﬁcant.
In conclusion, an 8-week treatment with 1500 mg ginsam
moderately improved the HbA1c level in type 2 diabetic patients
with inadequate glycemic control. The present study suggests
that 1500 mg ginsam might possibly be a viable option for glu-
cose lowering in patients with diabetes who do not trust
‘Westernized’ medicine and would prefer to use botanical
therapies without major side-effects, but future phase III clinical
studies are needed.
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Additional Supporting Information may be found in the online version of this article:
Table S1 | All-cause adverse events n (%) occurring in patients receiving placebo or ginsam
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